>>Signaling Pathways>> GPCR/G protein>> Adenosine Receptor>>N-[(4-Aminophenyl)methyl]adenosine

N-[(4-Aminophenyl)methyl]adenosine

Catalog No.GC36676

N-[(4-아미노페닐)메틸]아데노신은 아데노신 수용체 억제제이며, Rat ecto-5'-Nucleotidase에 대한 Ki는 29nM입니다.

Products are for research use only. Not for human use. We do not sell to patients.

N-[(4-Aminophenyl)methyl]adenosine Chemical Structure

Cas No.: 95523-13-0

Size 가격 재고 수량
5 mg
US$225.00
재고 있음
10 mg
US$338.00
재고 있음
50 mg
US$1,013.00
재고 있음
100 mg
US$1,768.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor, with Ki of 29 nM for Rat ecto-5′-Nucleotidase.IC50 value: 29.0 ± 1.7 nM (Ki) Target: Adenosine Receptor

[1]. Bhattarai S, et al. α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. J Med Chem. 2015 Aug 13;58(15):6248-63. [2]. Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-400. [3]. Zhu Z, et al. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorg Med Chem. 2008 Apr 1;16(7):3848-65.

리뷰

Review for N-[(4-Aminophenyl)methyl]adenosine

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-[(4-Aminophenyl)methyl]adenosine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.